Ferrous Fumarate
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ferrous Fumarate: From Iron Deficiency to Non-Syndromic Esophageal Malformation
One-Sentence Summary
Ferrous fumarate is an oral iron supplement, generally used to treat iron deficiency and iron-deficiency anaemia. The TxGNN model predicts it may be relevant to non-syndromic esophageal malformation, but there are 0 clinical trials and 0 publications supporting this, and no plausible biological link has been identified. This is an unverified computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency / iron-deficiency anaemia (general use; the SAHPRA registration records provided do not state an approved indication) |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ferrous fumarate is an oral iron salt. Its efficacy in replacing iron in iron deficiency is well established, but that mechanism does not obviously apply to the predicted new indication.
Non-syndromic esophageal malformation (for example oesophageal atresia or tracheo-oesophageal fistula) is a congenital structural defect that arises during embryonic development and is managed surgically. Iron replacement is not expected to correct or prevent such a defect, so no plausible mechanistic link was identified.
The high score (99.49%) cannot be traced to a biological pathway. It is most likely a knowledge-graph artefact, for example from network proximity or shared neighbouring nodes, and should not be read as evidence of benefit. Iron supplements can also irritate or injure the oesophagus, which is a safety concern rather than a benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. H0689 (Act 101/1965) | Autrin | Capsule | Not stated in the registration record provided |
| Reg. No. H2062 (Act 101) | Filibon | Capsule | Not stated in the registration record provided |
Both products are oral capsules. Essential Medicines List (EML) status could not be determined from the data provided.
Safety Considerations
- Drug Interactions: No interactions were found in the queried data (0 records). This is not confirmation that none exist.
- Oesophageal irritation: Oral iron supplements can cause oesophageal irritation or injury. This is relevant to any use in oesophageal conditions.
Please refer to the SAHPRA-approved Professional Information (PI) for full warnings and contraindications. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5). There are no trials or publications, and no plausible mechanism. The condition is a congenital structural defect that iron is not expected to affect, and oral iron may irritate the oesophagus.
To proceed, the following is needed:
- Mechanism of action data from DrugBank, and a documented biological rationale linking iron or ferrous fumarate to oesophageal development
- SAHPRA Professional Information (PI) for Autrin and Filibon, covering approved indications, warnings and contraindications
- Any supporting preclinical or clinical literature. If none is found, this prediction should be deprioritised.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.